Thyroid hormone (TH) is necessary for normal axonal myelination. Myelin basic protein (MBP) is a structural protein essential for myelin function. In this study, we demonstrate that perinatal hypothyroidism regulates MBP mRNA levels via indirect mechanisms. We observed decreased MBP mRNA accumulation in the hypothyroid rat brain at postnatal (PN) d 10 and 50. Acute TH replacement did not rescue hypothyroid MBP mRNA levels at PN5, 10, or 50. TH is necessary for normal intrahemispheric commissure development including the anterior commissure (AC) and the corpus callosum (CC). We determined that perinatal hypothyroidism decreases AC area and cellularity in the developing rat brain by PN10 and 50. In the developing CC, hypothyroidism initially increases area and cellularity by PN5, but then ultimately decreases area and cellularity by PN50. MBP-expressing oligodendrocytes are a recognized target of TH and are responsible for myelination within intrahemispheric commissures. We found that hypothyroidism reduces the number of mature oligodendrocytes within both the AC and CC. This reduction is noted at PN5, 10, and 50 in the AC and by PN10 and 50 in the CC. Together, these data suggest that TH regulates MBP mRNA levels through indirect mechanisms. These data demonstrate the complex mechanisms whereby TH regulates myelination in the developing brain.

No abstract

Objective-To determine whether serum contains an activity that induces artery calcification. Methods and Results-The elastic lamellae of devitalized rat aortas calcify rapidly in rat or bovine serum, or in human serum provided [Pi] Ն2 mmol/L. This calcification is attributable to a potent serum calcification factor (SCF), one that causes devitalized aortas to calcify when incubated in DMEM containing as little as 1.5% serum but not in DMEM alone. The SCF that initiates medial elastin calcification has the same 50-to 150-kDa size and protease sensitivity as the SCF shown previously to initiate calcification of type I collagen. Our working hypothesis is that the same SCF initiates calcification of collagen and elastin, and that this SCF arises from sites of normal bone mineralization and, like alkaline phosphatase, is released into general circulation. The SCF does not initiate medial elastin calcification in living arteries, which suggests that vascular cells may prevent this calcification. This hypothesis is supported by the observations that living arteries secrete the calcification inhibitor matrix Gla protein (MGP); that inactivation of MGP with warfarin causes living arteries to calcify; and that addition of MGP to medium containing warfarin prevents this calcification. Key Words: medial artery calcification Ⅲ elastic lamellae Ⅲ serum calcification factor Ⅲ matrix Gla protein Ⅲ devitalized and living arteries T wo major types of arterial calcification have been observed in human patients. 1,2 One affects the intimal layer of arteries and occurs within atherosclerotic plaques. The other involves the artery media and initially occurs within the elastic lamellae. This second type of vascular calcification is common in patients with chronic kidney disease and in patients with diabetes mellitus. Each type of arterial calcification has different physiological consequences, with clearcut evidence for adverse hemodynamic changes attributable to medial wall calcification but not to atherosclerotic plaque calcification, and the possible contribution of atherosclerotic plaque calcification to plaque rupture and subsequent thrombosis, an issue that does not apply to medial wall calcification. Conclusion-TheOur long-term goal is to understand the mechanisms that initiate calcification of the elastic lamellae of the artery media and the mechanisms that inhibit this calcification. In the course of our investigations, we became intrigued with the evidence for an association between bone metabolism and artery calcification, 3 an association that led us to propose that medial artery calcification is linked to bone resorption. One prediction of this hypothesis is that inhibitors of bone resorption should inhibit artery calcification. 3 In previous studies, we tested this prediction using 3 different types of bone resorption inhibitors, each with an entirely different mode of action on the osteoclast, the amino bisphosphonates alendronate and ibandronate, 3-5 the cytokine osteoprotegerin, 6 and the V-H ϩ -ATPase inhibitor SB...